Blood cancers aren’t like other cancers. There’s no lump that can be excised, no solid tumour that can be easily targeted for radiation. Because blood flows through your whole body, so does blood cancer. Many of the symptoms these cancers produce – fatigue, fever, swollen lymph nodes, bruising – are easily mistaken for something else. 

How do you treat something that seems so non-specific? For a significant number of patients, the answer is to get ultra-specific, according to groundbreaking research from the University of Auckland.

Stefan Bohlander, Peter Browett and Purvi Kakadiya are members of the Leukaemia and Blood Cancer Research Unit (LBCRU) at the Faculty of Medical and Health Sciences – professors Bohlander and Browett are the co-directors of the unit, while Kakadiya is a research fellow. The LBCRU sits within the University of Auckland’s Centre for Cancer Research, where Browett is one of the interim directors.

The principal funder for the LBCRU is Leukaemia & Blood Cancer New Zealand, which has contributed $2.8 million to date. 

Along with other team members, the three researchers work together on a highly personalised approach to blood cancers. Finding which specific genetic mutations led to a patient’s blood cancer can result in treatment that will work better for that patient. 

In some cases, drugs that target a particular mutation can be prescribed. In others, doctors can recommend more or less aggressive treatment depending on which mutations patients have. In yet other cases, knowing whether patients have an inherited predisposition to blood cancer can determine whether relatives should or shouldn’t donate their bone marrow.

This cutting-edge research is already leading to improved outcomes for some patients and likely saving lives.

All types of cancer are caused by mutations that arise in the cells of our bodies.

Environmental factors such as smoking, radiation exposure and obesity can increase the likelihood of some mutations, and some people carry inherited gene mutations that predispose them to cancer, but many cancers arise simply due to random mistakes in cell production.

Each of our cells contains 6 billion bases, analogous to letters in a book. The Bible – a tome 10 times longer than the average novel – contains about 3 million letters. That means the whole human genome, if written out, would be as long as 2,000 Bibles.

Each time our genetic “book” is copied – which happens a lot, since some of our cells, including blood cells, replicate every day – mutations, like typos, are possible. Some of these “typos” can be fixed by our bodies, while others are harmless, but some can lead to cancer.

The human genome project, which began in 1990 and finished in 2003, sequenced and mapped all the bases, which are paired and twisted into DNA molecules. Fortunately, not all the base pairs are equally important. We share 98 percent of our DNA with chimpanzees. Only about 1.2 percent of our DNA comprises genes, which are segments of DNA that code instructions for functions such as making proteins. Still, each of our cells holds about 22,000 genes.

Since Bohlander, who is the Marijana Kumerich Chair in Leukaemia and Lymphoma Research in the Department of Molecular Medicine and Pathology, began his research career some 35 years ago, our understanding of genes has improved dramatically. 

Not all 22,000 of our genes are relevant to blood cancer. Until about two years ago, blood cancer patients at Auckland City Hospital only had three genes routinely analysed for mutations, says Browett, who is both a consultant haematologist at Auckland City Hospital and Professor of Pathology in the Department of Molecular Medicine and Pathology.

“By looking for mutations in those three genes, we could classify some patients into good or unfavourable prognostic groups. But about 50 to 60 percent of patients had no mutations in those genes, so they were put into an intermediate group and all treated the same way.”

The researchers are also working on better ways to follow patients throughout their cancer journeys. Kakadiya has developed tests to monitor whether patients are responding to treatment and, once they’re in remission, whether they’re likely to relapse. 

“Traditionally when we treat a patient with leukaemia, we define remission as the bone marrow looking normal under the microscope and the blood count returning to normal, but those tests aren’t very sensitive,” says Browett. “Purvi [Kakadiya] has developed assays that can pick out a residual leukaemia cell or molecular biomarker down to a level of one in 100,000 or even one in a million.”

“If we monitor patients’ samples every three months, and after nine months, we see that the level of mutation is higher than last time, that tells us we should do something,” says Kakadiya. “This is cutting-edge science we’re doing and it’s actually impacting patient care. It’s adding a lot of information that’s helping clinicians, patients and families. That’s what’s driving me.”